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Molecular design of radiocopper-
labelled Affibody molecules
Vladimir Tolmachev  1, Tove J. Grönroos2,3,4, Cheng-Bin Yim2,5, Javad Garousi1, Ying 
Yue6, Sebastian Grimm6, Johan Rajander  5, Anna Perols6, Merja Haaparanta-Solin2,7, 
Olof Solin2,5,7, Riccardo Ferdani8, Anna Orlova9, Carolyn J. Anderson10 & Amelie Eriksson 
Karlström6
The use of long-lived positron emitters 64Cu or 61Cu for labelling of Affibody molecules may improve 
breast cancer patients’ stratification for HER-targeted therapy. Previous animal studies have shown 
that the use of triaza chelators for 64Cu labelling of synthetic Affibody molecules is suboptimal. In this 
study, we tested a hypothesis that the use of cross-bridged chelator, CB-TE2A, in combination with 
Gly-Glu-Glu-Glu spacer for labelling of Affibody molecules with radiocopper would improve imaging 
contrast. CB-TE2A was coupled to the N-terminus of synthetic Affibody molecules extended either with 
a glycine (designation CB-TE2A-G-ZHER2:342) or Gly-Glu-Glu-Glu spacer (CB-TE2A-GEEE-ZHER2:342). 
Biodistribution and targeting properties of 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-
ZHER2:342 were compared in tumor-bearing mice with the properties of 64Cu-NODAGA-ZHER2:S1, 
which had the best targeting properties in the previous study. 64Cu-CB-TE2A-GEEE-ZHER2:342 provided 
appreciably lower uptake in normal tissues and higher tumor-to-organ ratios than 64Cu-CB-TE2A-G-
ZHER2:342 and 64Cu-NODAGA-ZHER2:S1. The most pronounced was a several-fold difference in the 
hepatic uptake. At the optimal time point, 6 h after injection, the tumor uptake of 64Cu-CB-TE2A-GEEE-
ZHER2:342 was 16 ± 6%ID/g and tumor-to-blood ratio was 181 ± 52. In conclusion, a combination of 
the cross-bridged CB-TE2A chelator and Gly-Glu-Glu-Glu spacer is preferable for radiocopper labelling of 
Affibody molecules and, possibly, other scaffold proteins having high renal re-absorption.
A high level of human epidermal growth factor receptor type 2 (HER2) expression in breast and gastroesophageal 
cancer is a predictor for the response to HER2-targeting therapeutics (antibodies, antibody-drug conjugates, 
tyrosine kinase inhibitors)1,2. Several classes of radiolabelled probes for HER2 imaging (antibodies, antibody frag-
ments, engineered scaffold proteins) are under development for non-invasive in vivo assessment of HER2 expres-
sion in disseminated cancer3. Affibody molecules are high-affinity binders engineered using a non-antibody 
protein scaffold. Due to their small size and high affinity, radiolabelled Affibody molecules can visualize different 
cancer-associated molecular target proteins with a high contrast just a few hours after injection4. Clinical data 
recently demonstrated that PET using the anti-HER2 68Ga-ABY-025 Affibody molecule permits discrimination 
between breast cancer metastases with high and low levels of HER2 expression5. The largest difference between 
68Ga-ABY-025 uptake in HER2-positive and HER2-negative metastases was obtained when images were acquired 
at 4 h after injection. We postulated that an extension of the time interval between injection and imaging would 
further increase the difference in uptake values in HER2-positive and negative metastases, thereby minimizing 
the risk of false-positive findings. Increasing the imaging time post-tracer injection requires a more long-lived 
positron-emitting radionuclide than 68Ga (T1/2 = 67.6 min).
The use of longer-lived positron-emitting copper isotopes, 61Cu (T1/2 = 3.4 h) or 64Cu (T1/2 = 12.7 h), may 
provide a broader time window for PET imaging of HER2 expression using Affibody molecules. However, 
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besides selection of a nuclide with a suitable half-life and decay scheme, selection of an adequate labelling 
strategy is required. Since several studies suggested that the use of derivatives of the triazamacrocyclic chela-
tor NOTA (2-[4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl]acetic acid) provided adequate in vivo stability of a 
radiocopper label6–8, we earlier evaluated the use of NOTA and NODAGA (2-(4,7-bis-carboxymethyl-1,4,7-t
riazonan-1-yl)-pentanedioic acid) for labelling of Affibody molecules with 64Cu9. In that study, the chelators 
were conjugated to the N-terminus of the synthetic Affibody molecule ZHER2:S1 via an amide bond. Both 
64Cu-NOTA-ZHER2:S1 and 64Cu-NODAGA-ZHER2:S1 accumulated specifically in HER2-expressing xen-
ografts. Surprisingly, the biodistribution pattern of both conjugates differed appreciably from that of other 
radiometal-labelled Affibody molecules. There was a rapid decrease of the renal radioactivity and an increase of 
radioactivity accumulation in healthy tissues with time, which resulted in a decrease of tumor-to-organ ratios. 
This effect was most pronounced for 64Cu-NOTA-ZHER2:S1. One explanation for such an observation was a 
release of radiometabolites from kidneys and their re-distribution. This effect was not observed in the  majority 
of earlier studies because the renal reabsorption of the tested tracer was much lower. This reasoning was corrob-
orated by an observation of a similar effect for another polypeptide with a high renal reabsorption, A20FMDV2, 
which was labelled with 64Cu via NOTA monoamide10. Thus, a chelator with a higher metabolic stability or rapid 
excretion of radiometabolites is required for labelling of Affibody molecules or other proteins having high renal 
reabsorption with radiocopper.
The cross-bridged CB-TE2A (4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo[6.6.2]hexadecane) chelator 
provides a stable coupling of radiocopper to peptides and potentially meets our requirements11,12. However, pre-
vious studies have demonstrated that the use of chelators increasing the negative charge of the N-terminus of 
Affibody molecules is preferable due to reduced hepatic uptake13–15. The complex of Cu(II) with a monoamide 
derivative of CB-TE2A has a positive charge, which was considered as a potentially suboptimal property. Still, we 
have shown that the placement of a negatively charged triglutamyl spacer between the N-terminus of an Affibody 
molecule and a prosthetic group suppresses the hepatic uptake16. This was taken into account while designing 
the next generation of Affibody conjugates for labelling with radiocopper (Fig. 1). The aim of this study was to 
test the hypotheses that a) the use of monoamide CB-TE2A instead of monoamides of triaza chelators for radi-
ocopper labelling of Affibody molecules prevents deterioration of tumor-to-organ ratios with time, and b) the 
Figure 1. Structures of the chelators at the N-terminus of CB-TE2A-G-ZHER2:342 (a), CB-TE2A-GEEE-
ZHER2:342 (b) and NODAGA-ZHER2:S1 (c).
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use of a triglutamyl spacer between CB-TE2A and the N-terminus of the anti-HER2 Affibody molecule reduces 
undesirable hepatic uptake.
To test these hypotheses, we coupled CB-TE2A to the N-terminus of synthetic Affibody molecules 
extended either with a glycine (designation CB-TE2A-G-ZHER2:342) (Fig.  1a) or Gly-Glu-Glu-Glu 
spacer (CB-TE2A-GEEE-ZHER2:342) (Fig. 1b). The conjugates were labeled with 64Cu. Specificity of 
64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 binding to HER2-expressing cells and 
their cellular processing after binding was evaluated using SKOV-3 ovarian carcinoma cell line. Biodistribution 
of 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 was compared in BALB/C nu/nu mice 
bearing HER2-expressing SKOV-3 or HER2-negative Ramos lymphoma xenografts. The biodistribution was 
measured at 2, 6 and 24 h p.i. and compared with biodistribution of 64Cu-NODAGA-ZHER2:S1 (Fig. 1c), which 
had the best targeting properties in the previous study.
Results
Preparation and labeling of Affibody molecules. Affibody variants conjugated to the CB-TE2A che-
lator were successfully prepared by peptide synthesis and their identity was confirmed by mass spectrometry 
(Table 1). Purity of greater than 95% was obtained. Melting points (Table 1, Supplemental Figs S1 and S2) of 
both variants were close to the melting point of non-modified variant of ZHER2:342 (62.3 °C) and NODAGA-
ZHER2:S1 (63 °C)17. The equilibrium dissociation constants for binding to HER2 were in close range (KD = 60–90 
pM) for all Affibody variants used in this study. CD spectra demonstrated high-fidelity refolding of CB-TE2A-
containing Affibody molecules after thermal denaturation (Supplemental Figs S1 and S2).
Both CB-TE2A-G-ZHER2:342 and CB-TE2A-GEEE-ZHER2:342 were successfully labeled with 64Cu by 
incubation for 45 min at 95 °C in 0.55 M ammonium acetate, pH 5.6 followed by purification using NAP-5 
size-exclusion columns. The isolated labelling yield was 84 ± 5% for 64Cu-CB-TE2A-G-ZHER2:342 and 88 ± 3% 
for 64Cu-CB-TE2A-GEEE-ZHER2:342. The radiochemical purity of the conjugates was over 98%. The maxi-
mum obtained specific radioactivity was 4.2 MBq/µg (29.6 GBq/µmol) and 3.9 MBq/µg (28.9 GBq/µmol) for 
64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342, respectively. Challenge with 500-fold 
excess of EDTA did not cause any detectable release of radionuclide from conjugates (Supplemental Table S2).
Binding of both 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 to HER2-expressing 
SKOV-3 cells in vitro was efficiently prevented by pre-saturation of receptors by nonlabeled ZHER2:342 (Fig. 2), 
which demonstrated its HER2-specific nature. The internalization pattern (Fig. 3) was similar for both conjugates, 
and the internalized fraction at 24 h was approximately 25% for both variants. This was higher than the internal-
ized fractions of 64Cu-NODAGA-ZHER2:S1 at this time point (6 ± 1%)9.
Biodistribution Studies. To test HER2-specificity of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 
64Cu-CB-TE2A-G-ZHER2:342 accumulation in tumor in vivo, uptake of both tracers in HER2-positive 
(SKOV-3) and HER2-negative (Ramos lymphoma) xenografts was measured at 2 h post injection (p.i.). The 
results of the in vivo specificity tests are presented in Fig. 4. Uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 









CB-TE2A-G-ZHER2:342 7100 7099 60 63
CB-TE2A-GEEE-ZHER2:342 7487 7489 84 64
NODAGA-ZHER2:S1* 6977 6977 90 63
Table 1. Properties of the tracers. *Data from17.
Figure 2. In vitro specificity of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 binding 
to HER2-expressing SKOV-3 cells. In blocked groups, receptors were pre-saturated by 200-fold excess of 
nonlabeled ZHER2:342. Data are presented as the mean of three samples and standard deviation.
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xenografts (p < 1 × 10−4). The non-specific uptake in Ramos xenografts was negligible, at 40-to-90-fold lower 
than the uptake in SKOV-3 xenografts.
Data comparing the biodistribution of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 
and 64Cu-NODAGA-ZHER2:S1 in mice bearing HER2-positive SKOV-3 xenografts are presented in Table 2. At 
2 h after injection, the tumor uptake for all three conjugates was in the range of 14–17% ID/g. There was no signif-
icant difference between tumor uptake of the different conjugates at any of time points. Furthermore, there was no 
significant difference between tumor uptake at different time points for each conjugate. All variants demonstrated 
initially (2 h p.i.) a biodistribution pattern typical for Affibody molecules, i.e. clearance from the majority organs 
and tissues (although to different extent) and a high renal re-absorption of the tracers. Low initial radioactivity 
in intestines with content indicated negligible contribution of hepatobiliary excretion to clearance. The biodis-
tribution pattern of 64Cu-NODAGA-ZHER2:S1 was in a good agreement with the data published earlier9, i.e. 
relatively rapid decrease of radioactivity from kidneys (3-fold between 2 and 24 h) and gradual increase of radi-
oactivity uptake in other normal tissues over time. The biodistribution pattern of 64Cu-CB-TE2A-G-ZHER2:342 
and 64Cu-CB-TE2A-GEEE-ZHER2:342 was more typical for other radiometal-labeled Affibody molecules. 
Uptake in normal organs and tissues decreased over time for conjugates containing cross-bridged chelators. It 
should be noted that the uptake of CB-TE2A-conjugated variants was lower in the majority of normal organs 
compared with 64Cu-NODAGA-ZHER2:S1 at 2 h p.i. Renal radioactivity cleared more slowly compared with 
64Cu-NODAGA-ZHER2:S1, at approximately 2-fold between 2 and 24 h after injection. However, there was a clear 
difference between 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342. The most prominent 
was the difference in hepatic uptake, which was 5–7-fold lower for 64Cu-CB-TE2A-GEEE-ZHER2:342. In addi-
tion, the uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 in lung, spleen, muscle and bone was 1.5–2.5-fold lower.
The biodistribution features of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 
and 64Cu-NODAGA-ZHER2:S1 had a clear influence on their tumor-to-organ ratios (Table  3). 
64Cu-NODAGA-ZHER2:S1 demonstrated the lowest values at 2 h after injection, and the tumor-to-blood, 
Figure 3. Cellular processing of 64Cu-CB-TE2A-GEEE-ZHER2:342 (a) and 64Cu-CB-TE2A-G-ZHER2:342 (b) 
during incubation with HER2-expressing SKOV-3 cells. Data are presented as the mean of three samples and 
standard deviation. Values are normalized to the maximum cell-associated radioactivity. Error bars might not 
be visible because they are smaller than symbols.
Figure 4. Specificity of HER2-targeting in vivo. Biodistribution of 64Cu-CB-TE2A-GEEE-ZHER2:342 (a) or 
64Cu-CB-TE2A-G-ZHER2:342 (b) at 2 h p.i. in mice bearing either HER2-positive xenografts (SKOV-3) or 
HER2-negative xenografts (Ramos). The data are presented as mean ±SD for four mice.
www.nature.com/scientificreports/
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tumor-to-lung, and tumor-to-spleen ratios decreased over time. 64Cu-CB-TE2A-GEEE-ZHER2:342 demon-
strated the best ratios at all time points. Particularly important was the highest tumor-to-liver ratio. At 6 h after 
injection, tumor-to-blood and tumor-to-bone ratios for 64Cu-CB-TE2A-G-ZHER2:342 were significantly higher 
than at 2 h (p < 0.05), however there was no significant increase of any ratios from 6 to 24 h.
in vivo Imaging Studies. PET/CT imaging was performed at the same time point as measurements of bio-
distribution to verify the data and obtain a visual confirmation. The PET imaging results (Fig. 5) confirmed the 
ex vivo measurement data. Tumors were clearly visualized by all radiolabelled Affibody molecules. It has to be 
noted that the xenografts were small, which might result in an underestimation of the uptake in some tumors 
due to partial volume effect18. Indeed, the tumor weights in this study were ranging from 12 to 68 mg. Assuming 
a spherical shape for these tumors their diameters ranged approximately from 2.5 mm to 5 mm. The activity 
recovery coefficient (RC) of a PET scanner is dependent on the size of the object imaged and the energy of the 
β+ particles emitted by a particular radionuclide. Previous investigations19,20 demonstrated that the Inveon PET 
provides the RC for 18F varying from 0.15 for objects with 1 mm diameter to 0.97 for 5 mm objects. 64Cu and 
18F have similar β+ energies and one can expect a similarly low recovery for small tumors also for 64Cu. Besides 
tumors, very prominent radioactivity uptake was observed for all variants in kidneys and occasionally in bladder. 
In addition, high liver uptake was observed for 64Cu-NODAGA-ZHER2:S1 and 64Cu-CB-TE2A-G-ZHER2:342 
and accumulation of radioactivity in intestines was visualized for 64Cu-NODAGA-ZHER2:S1 at 6 and 24 h p.i. 
64Cu-CB-TE2A-GEEE-ZHER2:342 provided the best contrast for imaging of HER2-positive xenografts.
Uptake, % ID/g



















Blood 0.15 ± 0.03 0.29 ± 0.08 0.34 ± 0.08c 0.09 ± 0.01 0.11 ± 0.01b 0.43 ± 0.04c 0.07 ± 0.01 0.10 ± 0.01b 0.73 ± 0.04c
Lung 0.6 ± 0.2a 1.2 ± 0.3b 1.8 ± 0.2c 0.42 ± 0.03a 0.70 ± 0.04b 2.3 ± 0.4c 0.34 ± 0.05a 0.61 ± 0.08b 3.6 ± 0.2c
Liver 1.2 ± 0.1a 8.7 ± 0.4b 5.2 ± 0.7c 1.2 ± 0.1a 6.7 ± 0.8b 5.8 ± 0.4c 0.77 ± 0.07a 5.1 ± 0.2b 6.9 ± 0.6c
Spleen 0.40 ± 0.04a 1.0 ± 0.1 0.8 ± 0.2c 0.37 ± 0.02a 0.78 ± 0.02b 0.96 ± 0.08c 0.28 ± 0.02a 0.60 ± 0.09b 1.6 ± 0.2c
Stomach 0.51 ± 0.06a 0.9 ± 0.1 1.8 ± 0.2c 0.38 ± 0.02 0.57 ± 0.03b 2.0 ± 0.2c 0.22 ± 0.04 0.5 ± 0.2b 2.3 ± 0.3c
Kidney 364 ± 41 318 ± 17 349 ± 14 272 ± 18 252 ± 14 295 ± 43 185 ± 15a 141 ± 11b 111 ± 20c
Tumor 14 ± 5 17 ± 2 14 ± 5 16 ± 6 14 ± 3 12 ± 5 11 ± 3 14 ± 4 16 ± 5
Muscle 0.12 ± 0.01a 0.20 ± 0.03b 0.25 ± 0.02c 0.09 ± 0.01 0.13 ± 0.02b 0.27 ± 0.02c 0.06 ± 0.01 0.10 ± 0.01b 0.38 ± 0.04c
Bone 0.32 ± 0.09a 0.63 ± 0.06 0.5 ± 0.1c 0.19 ± 0.03 0.4 ± 0.1 0.6 ± 0.1c 0.14 ± 0.06a 0.39 ± 0.08b 0.8 ± 0.1c
Intestines* 1.1 ± 0.2a 1.7 ± 0.1b 3.5 ± 0.4c 0.8 ± 0.1 1.5 ± 0.1 5.3 ± 0.5c 0.3 ± 0.1a 1.1 ± 0.4b 5.6 ± 0.4c
Table 2. Biodistribution of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-
NODAGA-ZHER2:S1 in mice bearing HER2-positive (SKOV-3) xenografts. Data are presented as mean ± SD 
for four mice. *Data for intestines with content are presented as %ID per whole sample. aSignificant difference 
(p < 0.05) between 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 at this time point. 
bSignificant difference (p < 0.05) between 64Cu-CB-TE2A-G-ZHER2:342 and 64Cu-NODAGA-ZHER2:S1 at 
this time point. cSignificant difference (p < 0.05) between 64Cu-CB-TE2A-GEEE-ZHER2:342 64Cu-NODAGA-
ZHER2:S1 at this time point.
Tumor-to-organ ratio



















Blood 95 ± 21 61 ± 18 41 ± 8c 185 ± 66 134 ± 36b 29 ± 13c 162 ± 39 140 ± 53b 22 ± 7c
Lung 25 ± 6a 14 ± 4 8 ± 2c 39 ± 14a 20 ± 6b 6 ± 3c 34 ± 8 23 ± 7b 4 ± 1c
Liver 11 ± 3a 1.9 ± 0.2 3 ± 1c 13 ± 4a 2.2 ± 0.7 2.1 ± 0.9c 15 ± 3a 2.7 ± 0.8 2.3 ± 0.7c
Spleen 35 ± 8a 17 ± 3 18 ± 4c 44 ± 14a 18 ± 4 13 ± 5c 40 ± 12 24 ± 10 10 ± 3c
Stomach 28 ± 7 19 ± 4b 8 ± 2c 42 ± 13 25 ± 7b 6 ± 3c 53 ± 15 30 ± 15b 7 ± 2c
Kidney 0.04 ± 0.01 0.05 ± 0.01 0.04 ± 0.01 0.06 ± 0.02 0.06 ± 0.01 0.04 ± 0.02 0.06 ± 0.01 0.10 ± 0.03 0.14 ± 0.04c
Muscle 116 ± 35 86 ± 16 57 ± 19c 181 ± 52 118 ± 43b 47 ± 20c 194 ± 72 149 ± 59 41 ± 14c
Bone 46 ± 12a 27 ± 2 25 ± 5 87 ± 30a 38 ± 11 22 ± 6c 81 ± 7a 36 ± 4b 20 ± 8c
Table 3. Comparison of 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-
NODAGA-ZHER2:S1 tumor-to-organ ratios in nude mice bearing SKOV-3 xenografts. Data are presented as 
mean ± SD for four mice. aSignificant difference (p < 0.05) between 64Cu-CB-TE2A-GEEE-ZHER2:342 and 
64Cu-CB-TE2A-G-ZHER2:342 at this time point. bSignificant difference (p < 0.05) between 64Cu-CB-TE2A-G-
ZHER2:342 and 64Cu-NODAGA-ZHER2:S1 at this time point. cSignificant difference (p < 0.05) between 64Cu-
CB-TE2A-GEEE-ZHER2:342 and 64Cu-NODAGA-ZHER2:S1 at this time point.
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Discussion
Numerous studies have demonstrated that CB-TE2A is one of the best chelators for labelling of peptides with 
64Cu12. The main limitation of its use is the requirement of high temperature for complexation of copper21, which 
complicates its use for labelling of proteins with a tertiary structure, e.g. monoclonal antibodies, due to the risk of 
denaturation. This is not an issue for Affibody molecules, which are capable of rapid refolding under physiological 
conditions22. Although a chelator could interfere with this process, the CD spectra measurements demonstrated 
that both CB-TE2A-G-ZHER2:342 and CB-TE2A-GEEE-ZHER2:342 refold with high fidelity after thermal dena-
turation (Supplemental Figs S1 and S2). After labelling at 95 °C, both 64Cu-CB-TE2A-GEEE-ZHER2:342 and 
Figure 5. Maximum-intensity-projection PET/CT images of 64Cu-NODAGA-ZHER2:S1, 64Cu-CB-TE2A-
G-ZHER2:342 and 64Cu-CB-TE2A-GEEE-ZHER2:342 at 2, 6, and 24 h after injection in mice bearing HER2-
positive SKOV-3 xenografts. Arrows point at tumors. The scale was adjusted to provide clear visualization of 
hepatic uptake of 64Cu-CB-TE2A-G-ZHER2:342342 and 64Cu-NODAGA-ZHER2:S1. This resulted in saturation 
of tumor images (white spots).
www.nature.com/scientificreports/
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64Cu-CB-TE2A-G-ZHER2:342 retained the capacity of binding specifically to HER2-expressing cells both in vitro 
and in vivo (Figs 2 and 4). Conjugation of CB-TE2A and the amino acid linkers had essentially no effect on the 
affinity of the construct, which was in the range of 60–90 pM (Table 1).
The main finding of this study is that the use of CB-TE2A for labelling of Affibody dramatically changes 
the pattern of uptake in normal organs compared with the use of NODAGA (Table 2). While the uptake of 
radioactivity in blood, liver, lung, spleen, stomach, muscles and bones demonstrated an ascending trend for 
64Cu-NODAGA-ZHER2:S1, the trend was clearly descending for both variants labelled using CB-TE2A. This 
resulted in significantly increased tumor-to-organ ratios with time. The effect might be partially explained by 
better retention of renal catabolites of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 
compared to the retention of 64Cu-NODAGA-ZHER2:S1 radiometabolites, as the decrease of renal radioactivity 
over time is more pronounced for 64Cu-NODAGA-ZHER2:S1. This is in agreement with the data provided by 
Fani and co-workers8 for 64Cu-labed somatostatin antagonists showing higher retention of radioactivity kidneys 
when CB-TE2A was used instead of NODAGA. It has to be noted that that absolute renal uptake of somatostatin 
analogues was much lower compared to Affibody molecules, and re-distribution of radiometabolites had no 
obvious effect of uptake in normal tissues. It is also possible that the radiometabolites are excreted more rap-
idly in the case of cross-bridged chelators. The high kinetic stability of the 64Cu-CB-TE2A chelate compared to 
64Cu-NODAGA may also account for increased clearance of the CB-TE2A-Affibody constructs from organs other 
than the kidneys.
Another essential finding is the role of a linker between a chelate and the N-terminus of Affibody mole-
cules. Incorporation of a chelator/radiometal complex alters the charge of an imaging probe both locally and 
globally and affects off-target interactions and consequently on normal tissue uptake. Earlier study suggested 
that a negative charge of a radionuclide-chelator complex at the N-terminus of an anti-HER2 Affibody mol-
ecule is preferable13–15 and a positively charged monoamide-CB-TE2A/Cu(II) complex might slow down the 
blood clearance and increase the hepatic uptake. In fact, the liver uptake of 64Cu-CB-TE2A-G-ZHER2:342 was 
approximately four-fold higher than the uptake of the same molecules labelled with 111In using DOTA23. The 
present study demonstrated that this effect can be counteracted by the incorporation of a negatively charged 
triglutamyl linker. The hepatic uptake of 64Cu-CB-TE2A-GEEE-ZHER2:342 was 5-6-fold lower than the uptake 
of 64Cu-CB-TE2A-G-ZHER2:342 (Table 2), which translated into substantially higher tumor-to-liver ratios 
(Table 3). This is a critical aspect since both breast and esophageal cancers often have liver metastases24.
It has to be noted that there may be an alternative approach to avoiding the positive charge of the 
radiocopper-CB-TE2A complex at N-terminus of affibody molecules. Synthesis of CB-TE2A derivatives featuring 
an additional orthogonally protected arm for conjugation has been reported25,26. Such derivatives would provide a 
neutral complex with Cu2+. However, the use of oligoglutamate linker provides more straightforward and flexible 
way for modification of N-terminal charge for affibody molecules.
Overall, 64Cu-CB-TE2A-GEEE-ZHER2:342 provides the best tumor-to-organ ratios among the tested var-
iants. Biodistribution data suggest that imaging at 6 or 24 h after injection would improve the tumor-to-blood 
ratios and therefore increase the sensitivity of imaging. Better retention of Affibody molecules in tumors with 
high expression, which was observed both in preclinical27 and clinical studies5, should ensure reliable discrimina-
tion between metastases with high and low HER2 expression at later time points.
Recent clinical studies demonstrated that the elevated renal uptake of Affibody molecules5 or nanobodies28 
does not complicate PET imaging of metastases in the lumbar area and is associated with an acceptable level of 
renal and whole body absorbed doses. This provides a rationale for the use of scaffold protein-based imaging 
probes with high renal uptake, such as DARPins29, fibronectin domain derivatives30, or ADAPTs31. Some of them, 
e.g. EGFR-targeting Affibody molecules32, would have increased sensitivity of imaging when used several hours 
or at the next day after injection. We hope that the results of this study would help to choose the optimal labeling 
approach for such imaging agents. Of course, a clinical translation would require a careful optimization of dosim-
etry for each imaging agent. For example, data from this study suggest that the optimum time point for imaging 
would be around 6 h after injection, since there is no significant increase of tumor-to-organ ratios after this. This 
indicates that 61Cu (T1/2 = 3.4 h) might be a preferable copper radioisotope for labeling of anti-HER2 Affibody 
molecules. This radionuclide might be produced by the 60Ni(d,n)61Cu or 61Ni(p,n) 61Cu nuclear reactions using 
low-energy cyclotrons available at PET centers33,34. Preliminary estimations suggest that the renal and whole body 
doses would be similar in this cases to doses due to imaging using 68Ga-labeled Affibody molecules.
In conclusion, this study confirmed our hypotheses that the use of monoamide CB-TE2A instead of mono-
amino derivatives of triaza chelators for radiocopper labelling of Affibody molecules prevents deterioration of 
tumor-to-organ ratios with time, and the use of a triglutamyl spacer between CB-TE2A and the N-terminus of the 
anti-HER2 Affibody molecule reduces undesirable hepatic uptake. The combination of CB-TE2A and a negatively 
charged Gly-Glu-Glu-Glu linker is a suitable variant for labelling of Affibody molecules with radiocopper.
Methods
Radioactivity measurements, analysis and data treatment. VDC-405 ionization chamber 
(Veenstra Instruments) was used for radioactivity measurement during formulation of solutions for injections. 
Radioactivity of samples from in vitro and in vivo studies was measured using an automated gamma spectrome-
ter (Wizard2, PerkinElmer). Purity, yield and stability of radiolabelled Affibody molecules were measured using 
radio-instant thin-layer chromatography (radioITLC) with ITLC-SG strips (Agilent). The strips were developed 
with 0.2 M citric acid, pH 2. Radioactivity distribution along the strips was measured using BAS-TR2025 imaging 
plates (Fuji Photo Film Co.) scanned with an FLA-5100 scanner (both from Fuji Photo Film Co). RadioITLC 
analysis was validated using a blank experiment and radio-reversed phase high performance liquid chroma-
tography (radio-HPLC). For radio-HPLC, a Jupiter Proteo C12 column (4.6 × 250 mm) was eluted with a linear 
CH3CN/H2O gradient (10–70% CH3CN in 12 min) in 0.1% trifluoroacetic acid at a flow rate of 1.0 mL/min.
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The data are presented as the mean +/− standard deviation. An unpaired two-tailed t-test was used to find a 
significant difference (P < 0.05) between two sets of data. One-way ANOVA analysis with Bonferroni’s multiple 
comparison test using Prism 5 software (GraphPad Software) was used to evaluate differences between more than 
two sets.
Synthesis and characterization of Affibody molecules. The chelator CB-TE2A was synthesized as 
previously described11.
The Affibody molecule ZHER2:342 with the sequence VENKFNKEMRNAYWEIALL PNLNNQQKRAFIRSLY 
DDPSQSANLLAEAKKLNDAQAPK was synthesized using standard Fmoc chemistry on a 433A Peptide 
Synthesizer (Applied Biosystems) as described earlier17. The N-terminus of the synthesized Affibody mole-
cule was extended manually by coupling of Gly (variant G-ZHER2:342) or Gly-Glu-Glu-Glu sequence (variant 
GEEE-ZHER2:342). The CB-TE2A chelator (10 mol equivalents) was conjugated to the peptide using 10 mol equiv-
alents of N′,N′-dicyclohexylcarbodiimide and N-ethyldiisopropylamine. The molar excess of the chelator was used 
to ensure nearly 100% conjugation yield. Deprotection of the protecting groups and release of the peptide from the 
resin were achieved by treatment with a mixture of H2O/TIS/TFA (2.5:2.5:95) for 2 h at RT. The deprotected peptide 
was extracted between H2O and tert-butyl methyl ether, followed by lyophilization of the aqueous phase. Analysis of 
the conjugates was performed by RP-HPLC using a SOURCETM 5RPC column, a 20 min gradient of 20–50% B (A: 
0.1%TFA-H2O, B: 0.1%TFA-CH3CN) and a flow rate of 1 mL/min. The purification was performed using a Zorbax 
CB300-C18 column. Mass spectrometric analysis was carried out on a Bruker MALDI mass spectrometer (CCA 
matrix) to confirm the protein mass.
The affinity of CB-TE2A-GEEE-ZHER2:342 and CB-TE2A-G-ZHER2:342 binding to the extracellular 
domain of HER2 (R&D systems) was measured in duplicate with concentrations of 0.25, 0.5, 1, 2, 3, 5, and 10 nM 
using Biacore 2000 as described earlier17. The curve fitting (Langmuir 1:1 binding model) was performed using 
BiaEval software (Biacore AB, Sweden).
Circular dichroism studies were performed with 40 µM protein in PBS (pH 7.4) using a Jasco J-810 spectropo-
larimeter17. For the variable temperature measurements, the signal was recorded at 221 nm and the temperature 
was increased from 20 to 90 °C at a rate of 5 °C/min. Circular dichroism spectra were recorded from 250 to 
195 nm at 20 °C before and after the melting.
The Affibody molecule NODAGA-ZHER2:S1 containing the NODAGA chelator conjugated via amide bond 
at the N-terminus was synthesized, purified and characterized as described earlier17. This Affibody molecule has 
a sequence AEAKYAKEMRNAYWEIALLPNL TNQQKRAFIRKLYDDPSQSSELLSEAKKLNDSQAPK, and bio-
distribution of 68Ga- and 111In-labeled DOTA conjugated ZHER2:S1and ZHER2:342 are very similar35,36.
Copper-64 was produced using the 64Ni(p,n)64Cu nuclear reaction and separated and purified by anion 
exchange chromatography, as previously described37. The radionuclide was prepared as a solution in 0.04 M HCl 
with effective specific radioactivity of 3 TBq/μmol at the end of bombardment.
For radiolabeling, Affibody molecule, 50 µg in 50 µL 0.55 M ammonium acetate, pH 5.6, was mixed with 150–
270 MBq 64CuCl2 in 10 µL 0.04 M HCl, and the mixture was incubated for 45 min at 95 °C. A 500-fold excess of 
Na4EDTA (10 mg/mL in water, 137 µL) was added to the mixture followed by additional incubation at 95 °C for 
10 min. The radiolabeled Affibody molecules were purified using disposable NAP-5 size-exclusion columns (GE 
Healthcare). The label stability was tested by incubation of labeled Affibody molecules with a 500-fold excess of 
Na4EDTA during 1 h.
NODAGA-ZHER2:S1 was labeled with 64Cu for comparative in vivo studies as described earlier9. As 
HER2-postitive cells, SKOV-3 ovarian carcinoma cell line (1.2 × 106 receptors per cell)22 was used for in vitro and 
in vivo studies. Ramos lymphoma cell line was used for implantation of HER2-negative xenografts. Both cell lines 
were purchased from American Type Tissue Culture Collection (ATCC) via LGC Standards (Teddington, UK) 
and cultivated according to ATCC recommendations.
The specificity of 64Cu-CB-TE2A-GEEE-ZHER2:342 and 64Cu-CB-TE2A-G-ZHER2:342 binding to 
HER2-expressing SKOV-3 cells was evaluated by a saturation assay using a 200-fold molar excess of non-labelled 
ZHER2:342 Affibody molecules9.
To evaluate internalization, SKOV-3 cells were incubated with the conjugates (1 nM) and the internalized 
radioactivity was measured at 1, 2, 4, 8 and 24 h using a modified acid wash method, as described earlier38. The 
cells were incubated at 37 °C with the labeled compounds (concentration 1 nM). A set of three dished was used 
for each data point. The incubation medium from a dishes was removed. The cells were washed ice cold medium. 
The membrane-bound radioactivity was removed by treatment with 0.5 mL of 0.2 M glycine buffer containing 4 M 
urea, pH 2.0, for 5 min on ice. Dishes were additionally washed with 0.5 mL acidic buffer and by 1 mL PBS, and the 
fractions were pooled. To collect radioactivity internalized by the cells, the cells were treated them with 0.5 mL of 
1 M NaOH at 37 °C for 0.5 h. The dishes were additionally washed with 0.5 mL NaOH solution followed by 1 mL 
PBS. The radioactivity in acidic (cell bound) and alkaline (internalized) fraction was measured.
Biodistribution Studies. Animals were cared for in compliance with the guidelines of the International 
Council of Laboratory Animal Science. All animal procedures were approved by the Animal Ethics Committee 
of the Provincial Government of Southern Finland, and performed following the guidelines of the European 
Community Council Directives 86/609/EEC.
HER2-positive xenografts were obtained by subcutaneous inoculation of 1 × 107 SKOV-3 cells in female 
BALB/C nu/nu mice (Scanbur, 8 weeks old at arrival). HER2-negative control tumors were obtained by inocu-
lation of 1 × 107 Ramos lymphoma cells. Experiments were performed 20 days after implantation. The average 
tumor weight was 38 ± 22 mg at the time of the experiment.
A group of four mice per data point was used for ex vivo measurements. Mice bearing SKOV-3 xenografts 
were injected via the tail vein with 64Cu-CB-TE2A-G-ZHER2:342, 64Cu-CB-TE2A-GEEE-ZHER2:342 or 
www.nature.com/scientificreports/
9SCIEnTIFIC RePORtS |  (2018) 8:6542  | DOI:10.1038/s41598-018-24785-2
64Cu-NODAGA-ZHER2:S1 (450 kBq in 100 µL per mouse). The injected protein dose was adjusted to 5 µg (0.7 
nmol). Biodistribution was measured 2, 6, and 24 h post-injection. Mice bearing HER2-negative Ramos lym-
phoma xenografts were injected with the same amounts of protein and radioactivity, and biodistribution was 
measured 2 h after injection. The animals were exsanguinated under anesthesia, the organs and tissues of interest 
were excised and their weight and radioactivity were measured. Radioactivity of gastrointestinal tract (with con-
tent) was also measured to evaluate hepatobiliary excretion.
in vivo Imaging Studies. SKOV-3 (n = 2) xenograft-bearing mice were injected via the tail vein with 
64Cu-CB-TE2A-G-ZHER2:342 (13.1 ± 0.9 MBq, 5 µg, 100 µL). 64Cu-CB-TE2A-GEEE-ZHER2:342 (16.6 ± 0.05 
MBq, 5 µg, 100 µL) or 64Cu-NODAGA-ZHER2:S1 (12.3 ± 0.9 MBq, 5 µg, 100 µL). Mice were anesthetized using 
2.5% isoflurane/O2, and positioned on a heating pad two at a time in a PET/CT scanner (Siemens Medical 
Solutions, Inc.) for CT acquisition (10 min) and PET scan in list mode (20 min). Mice were scanned at 2, 6, 
and 24 h post-injection. PET images were reconstructed using an FBP algorithm of two iterations, followed by 
maximum a posteriori (MAP, 18 iterations) integrative algorithms (Inveon Acquisition Workplace, version 2.0; 
Siemens Preclinical Solutions). Data were decay-corrected to the time of injection.
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